for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Quest Diagnostics Inc

DGX.N

Latest Trade

123.29USD

Change

0.47(+0.38%)

Volume

328,726

Today's Range

122.39

 - 

123.73

52 Week Range

73.03

 - 

131.60

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
122.82
Open
122.80
Volume
328,726
3M AVG Volume
24.26
Today's High
123.73
Today's Low
122.39
52 Week High
131.60
52 Week Low
73.03
Shares Out (MIL)
134.77
Market Cap (MIL)
16,762.19
Forward P/E
12.43
Dividend (Yield %)
1.80

Next Event

Dividend For DGX.N - 0.5600 USD

Latest Developments

More

Quest Diagnostics Inc - Lifted Temporary Suspension, Announced On April 22, 2020, Of Company's Common Stock Repurchase Program

Adage Capital Partners GP LLC Dissolves Share Stake In Moderna, Takes In Gilead Sciences

Quest Diagnostics Reports Third Quarter 2020 Financial Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Quest Diagnostics Inc

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs). Its Diagnostic Solutions group includes its risk assessment services business, which offers solutions for insurers, and its healthcare information technology businesses, which offers solutions for healthcare providers. The Company's services are provided under the Quest Diagnostics brand, but it also provides services under other brands, including AmeriPath, Dermpath Diagnostics, Focus Diagnostics, Athena Diagnostics, ExamOne, Quanum and Care360.

Industry

Healthcare Facilities

Contact Info

500 Plaza Dr

SECAUCUS, NJ

07094-3619

United States

+1.973.5202700

https://www.questdiagnostics.com/

Executive Leadership

Stephen H. Rusckowski

Chairman of the Board, President, Chief Executive Officer

Mark J. Guinan

Chief Financial Officer, Executive Vice President

James E. Davis

Executive Vice President, General Diagnostics

Michael E. Prevoznik

Senior Vice President, General Counsel

Catherine T. Doherty

Senior Vice President, Group Executive - Clinical Franchise Solutions and Marketing

Key Stats

2.00 mean rating - 18 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

7.7K

2018

7.5K

2019

7.7K

2020(E)

9.1K
EPS (USD)

2017

5.670

2018

6.310

2019

6.560

2020(E)

10.036
Price To Earnings (TTM)
15.41
Price To Sales (TTM)
2.00
Price To Book (MRQ)
2.62
Price To Cash Flow (TTM)
11.50
Total Debt To Equity (MRQ)
71.45
LT Debt To Equity (MRQ)
62.78
Return on Investment (TTM)
10.35
Return on Equity (TTM)
8.51

Latest News

Latest News

BRIEF-U.S. FDA Says Authorizes First Covid-19, Flu Combination Test For Use With Home-Collected Samples

* U.S. FDA SAYS AUTHORIZES FIRST COVID-19 AND FLU COMBINATION TEST FOR USE WITH HOME-COLLECTED SAMPLES

Quest Diagnostics reports rise in turnaround time on COVID-19 testing demand surge

Quest Diagnostics Inc <DGX.N> said on Tuesday the nationwide surge in coronavirus cases has led to a slight increase in turnaround time for its COVID-19 testing.

Quest raises profit forecast as COVID-19 tests demand to jump

Quest Diagnostics Inc <DGX.N> raised its full-year earnings expectations on Thursday after a strong quarterly beat and forecast robust demand for COVID-19 tests during the fall season and into 2021.

Quest Diagnostics third-quarter profit more than doubles

Quest Diagnostics Inc reported a 164% rise in third-quarter profit on Thursday, as demand for tests offered by the clinical lab operator recovered on easing of COVID-19 related restrictions.

FACTBOX-Drugmakers rush to develop COVID-19 treatments

Drugmakers around the world are rushing to develop treatments for COVID-19, the respiratory disease caused by the novel coronavirus that has killed hundreds of thousands. Several companies are developing antibody treatments, similar to Regeneron Pharmaceutical Inc's treatment...

Walmart to test drone delivery of COVID-19 test kits

Walmart Inc said on Tuesday it would run a pilot project to deliver self-collection test kits for coronavirus through automated drones at customers' doorsteps.

Breakingviews - Corona Capital: Testing, Flights, Football

Corona Capital is a column updated throughout the day by Breakingviews columnists around the world with short, sharp pandemic-related insights.

Quest Diagnostics raises 2020 profit, revenue forecast

Quest Diagnostics <DGX.N> on Thursday raised its full-year revenue and profit forecast, benefiting from growing demand for its non-COVID-19 testing services.

Florida cuts ties with Quest over 75,000 COVID-19 test results backlog

Florida on Tuesday cut ties with Quest Diagnostics Inc as the medical device maker failed to share the results of nearly 75,000 COVID-19 tests dating back to April with the state health department in a timely manner due to a technical issue.

Delta partners with CVS Health for rapid COVID-19 tests

(The story corrects to say that partnership with Mayo and Quest is ongoing in paragraph 3 on story from Aug 18)

Quest medical lab sees COVID-19 test speed at 'acceptable' level by September

Quest Diagnostics Inc <DGX.N> said on Thursday it expects to cut week-long turnaround times for COVID-19 tests by more than half to get to "acceptable" levels by September, responding to concerns that slow testing is hampering the U.S. response.

Quest expects COVID-19 tests turnaround time at 'acceptable' levels by Sept

Quest Diagnostics Inc said on Thursday it expects to get turnaround times for COVID-19 tests to "acceptable" levels by this September by boosting capacity and prioritizing the most at-risk patients.

Quest says many U.S. COVID-19 tests taking more than a week

Quest Diagnostics Inc said on Monday the turnaround for COVID-19 tests it is conducting in the United States has lengthened, with non-prioritized patients waiting a week or more on average for their results.

Quest sees Q2 revenue above estimates on demand for COVID-19 testing services

Quest Diagnostics reported preliminary second-quarter revenue above analysts' estimates on Monday, largely due to growing demand for its COVID-19 testing services.

BRIEF-Quest Diagnostics Says Turnaround Time For Tests Now 4-6 Days As Demand For COVID-19 Molecular Diagnostic Testing Continues To Surge

* QUEST DIAGNOSTICS SAYS DEMAND FOR COVID-19 MOLECULAR DIAGNOSTIC TESTING CONTINUES TO SURGE, CAUSING FURTHER DELAYS IN TURNAROUND TIMES

BRIEF-Humana To Offer Labcorp At-Home COVID-19 Test Collection, Collaborate With Walmart And Quest Diagnostics To Offer Drive-Thru Testing For Humana Members

* HUMANA TO OFFER LABCORP AT-HOME COVID-19 TEST COLLECTION AND COLLABORATE WITH WALMART AND QUEST DIAGNOSTICS TO OFFER DRIVE-THRU TESTING FOR HUMANA MEMBERS Source text for Eikon: Further company coverage:

BRIEF-Quest Diagnostics To Expand In Indiana With Acquisition Of Outreach Lab Businesses Of Community Health Network And Ascension St. Vincent

* QUEST DIAGNOSTICS TO EXPAND IN INDIANA WITH ACQUISITION OF OUTREACH LAB BUSINESSES OF COMMUNITY HEALTH NETWORK AND ASCENSION ST. VINCENT NOW SERVICED THROUGH MID AMERICA CLINICAL LABORATORIES

Quest Diagnostics sees faster-than-expected recovery in U.S. testing volumes

Quest Diagnostics said on Wednesday it saw a higher recovery in its testing volumes in the United States where state and local governments were slowly lifting restrictions after the coronavirus lockdowns.

BRIEF-Quest Diagnostics - Adj EPS For Q2 Of 2020 Could Be In Range Of Breakeven To Slightly Profitable

* QUEST DIAGNOSTICS INC - BELIEVES THAT ITS ADJUSTED EARNINGS PER SHARE FOR Q2 OF 2020 COULD BE IN RANGE OF BREAKEVEN TO SLIGHTLY PROFITABLE

BRIEF-Home State Health And Quest Diagnostics Team Up To Increase Access To Covid-19 Testing In Underserved Communities

* HOME STATE HEALTH AND QUEST DIAGNOSTICS TEAM UP TO INCREASE ACCESS TO COVID-19 TESTING IN UNDERSERVED COMMUNITIES Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up